<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Hypoxia expedites the progression of papillary thyroid carcinoma by promoting the CPT1A-mediated fatty acid oxidative pathway</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Zhou</forename><surname>Liang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Zhantansi Outpatient</orgName>
								<orgName type="department" key="dep2">Central Medical District of Chinese</orgName>
								<orgName type="institution">PLA General Hospital</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">Hongsheng</forename><surname>He</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bing</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Zhantansi Outpatient</orgName>
								<orgName type="department" key="dep2">Central Medical District of Chinese</orgName>
								<orgName type="institution">PLA General Hospital</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zhentian</forename><surname>Kai</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><surname>Liang Zong</surname></persName>
							<idno type="ORCID">0009-0008-9534-0214</idno>
							<affiliation key="aff2">
								<orgName type="department">College of Otolaryngology Head and Neck Surgery</orgName>
								<orgName type="institution">Chinese PLA General Hospital</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">National Clinical Research Center for Otolaryngologic Diseases</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Liang</forename><surname>Zong</surname></persName>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">College of Otolaryngology Head and Neck Surgery</orgName>
								<orgName type="institution">Chinese PLA General Hospital</orgName>
								<address>
									<addrLine>28 Fuxing Rd</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution">Haidian District</orgName>
								<address>
									<postCode>100853</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Hypoxia expedites the progression of papillary thyroid carcinoma by promoting the CPT1A-mediated fatty acid oxidative pathway</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">B0518261DEC2EC83DE78083BF3504DCE</idno>
					<idno type="DOI">10.1002/ddr.22168</idno>
					<note type="submission">Received: 27 November 2023 | Revised: 8 February 2024 | Accepted: 23 February 2024</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-06-12T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>carnitine palmitoyl-transferase 1A</term>
					<term>HIF-1α</term>
					<term>hypoxia</term>
					<term>lipid metabolism reprogramming</term>
					<term>papillary thyroid carcinoma Liang</term>
					<term>Z.</term>
					<term>He</term>
					<term>H.</term>
					<term>Zhang</term>
					<term>B.</term>
					<term>Kai</term>
					<term>Z.</term>
					<term>&amp;</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Hypoxia has been reported to promote the proliferation and migration of thyroid cancer, while the special mechanism was still unclear. HIF-1α/carnitine palmitoyltransferase 1A (CPT1A) was found to be associated with papillary thyroid carcinoma (PTC) but the biological role of CPT1A in PTC was not explored. The effects of hypoxia and carnitine palmitoyl-transferase 1A (CPT1A) expression on PTC cells were determined by cell counting kit-8 assay, detection of oxidative stress, inflammation response and mitochondrial membrane motential (MMP). Oil Red O staining and the detection of free fatty acids were performed to assess the status of lipid metabolism. Flow cytometric analysis was performed to assess cell apoptosis. Quantitative polymerase chain reaction (qPCR) and western blot analysis were applied to investigate the expressions of CPT1A and HIF-1α and the molecules involved cell function. The expressions of CPT1A and HIF-1α were significantly increased in PTC cells with or without hypoxia treatment. CPT1A overexpression or silencing promoted or inhibited cell viability, and hypoxia further repressed cell viability. In addition, CPT1A overexpression alleviates hypoxia-induced increased oxidative stress, inflammation response and elevated MMP. CPT1A overexpression enhanced palmitic acid-induced decreased cell growth, enhanced the metabolic capacity of free fatty acid and suppressed cell apoptosis. Animal experiments showed that CPT1A overexpression promoted PTC tumor growth, reduced lipid deposition, oxidative stress and inflammation, as well as enhancing cell function indicators. However, CPT1A silencing showed the opposite effects both in vitro and in vivo. Hypoxia induces the high expression of HIF-1α/CPT1A, thereby reprogramming the lipid metabolism of PTC cells for adapting the hypoxia environment, meanwhile inhibiting the cell damage and apoptosis caused by oxidative stress.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">| INTRODUCTION</head><p>Thyroid cancer is the most common primary endocrine malignancy with rapidly increasing mortality <ref type="bibr" target="#b5">(Chen et al., 2023)</ref>. Papillary thyroid carcinoma (PTC) is the commonest subtype of thyroid cancer and its risk factors includes ionizing radiation exposure, thyroid nodular disease and the family history <ref type="bibr" target="#b25">(Mao et al., 2020)</ref>. However, the specific mechanism underlying PTC has not been elucidated so far.</p><p>Although PTC is generally recognized as a kind of tumor with low malignancy degree and slow progression and good prognosis than many other types of cancers, some studies have found that mutations of some different genes can cause significant changes in biological behavior and physiology such as tumor progression and metastasis <ref type="bibr" target="#b20">(Lin et al., 2022;</ref><ref type="bibr" target="#b26">Mastronikolis et al., 2020;</ref><ref type="bibr" target="#b37">Yan et al., 2021)</ref>.</p><p>Hypoxia promotes a plethora of genetic and epigenetic changes that effectively alter the dynamics of the tumor microenvironment, leading to increased glycolysis, angiogenesis, and metabolic alterations <ref type="bibr" target="#b9">(Hompland et al., 2021)</ref>. In the hypoxic tumor microenvironment, poor vascularization and nutrient and oxygen deprivation lead to adaptive metabolic cancer cell reprogramming <ref type="bibr" target="#b30">(Ryan et al., 2000;</ref><ref type="bibr" target="#b36">Xia et al., 2021)</ref>. Hypoxia-induced upregulation of HIF-1α expression promotes fatty acid metabolism and reduces intracellular lipid accumulation to meet cellular energy requirements <ref type="bibr" target="#b29">(Rios-Colon et al., 2021)</ref>. Long chain fatty acids are an important source of lipid energy metabolism in cells, especially mitochondria, and have a close influence on the proliferation and metastasis of various tumors <ref type="bibr" target="#b6">(Chu et al., 2023)</ref>. High fat diet containing mainly palmitic acid can cause the occurrence of B-Raf (V600E) mutation in thyroid cancer (one of the most common mutations in PTC, giving cells greater proliferation and metastasis capacity) <ref type="bibr" target="#b13">(Kim et al., 2022)</ref>. Moreover, the growth of B-Raf (V600E) mutant cancer cells was significantly inhibited by hyperactivation of MAPK protein phosphatase 2A with long-chain fatty acid analogs <ref type="bibr" target="#b1">(Atiq et al., 2016)</ref>.</p><p>Carnitine palmitoyl-transferase 1A (CPT1A) is one of the most common carnitine palmitoyl transferase 1 (CPT1) family of rate-limiting enzyme for β-oxidation of long chain fatty acids, which is regulated by many factors at the gene and protein levels <ref type="bibr" target="#b18">(Li et al., 2022;</ref><ref type="bibr" target="#b31">Schlaepfer &amp; Joshi, 2020;</ref><ref type="bibr" target="#b35">Wang et al., 2018)</ref>. Deficiency or reduction of CPT1A activity lead to limited oxidation of normal fatty acids, resulting in dysfunctions of cells and tissues <ref type="bibr" target="#b8">(Hao et al., 2021;</ref><ref type="bibr" target="#b10">Huang et al., 2021)</ref>.</p><p>One study has found that the expression levels of three key enzymes LPL, FATP2 and CPT1A were significantly increased in PTC using metabolomics, proteomic and lipidomics test and high levels of FATP2 and CPT1A may lead to poor prognosis of PTC <ref type="bibr" target="#b22">(Lu et al., 2021)</ref>. In addition, ectopic overexpression of LPL, FATP2 and CPT1A can promote the migration of thyroid cancer cells <ref type="bibr" target="#b22">(Lu et al., 2021)</ref>. Lack of CPT1A will prevent cells from meeting the increased energy demands of growth in a hypoxic environment, due to the regulatory role of CPT1A in fatty acid oxidation <ref type="bibr" target="#b29">(Rios-Colon et al., 2021)</ref>.</p><p>In this study, we explored the biological roles and mechanisms of CPT1A in PTC cell growth, oxidative stress and apoptosis under hypoxia. We provide evidence to support that CPT1A could be a novel therapeutic target for the treatment of PTC patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">| MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">| Cell culture and treatment</head><p>Human PTC lines TPC-1, IHH-4, GLAG-66 and normal thyroid cells Nthy-ori 3-1 were obtained from Type Culture Collection of the Chinese Academy of Sciences and the cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin in a humidified 5% CO 2 atmosphere at 37°C. To establish an in vitro hypoxia model, TPC-1 cells were cultured in a Modular Incubator Chamber (Billups-Rothenberg Inc.) with 1% O2, 94% N 2 and 5% CO 2 at 37°C for 12, 24, 48 and 72 h. After that, the cells were transferred back to full culture medium at an atmosphere with 95% O 2 and 5% CO 2 at 37°C. Normal TPC-1 cells were incubated in a regular cell culture condition as a normoxia control. Besides, to research fatty acid metabolism, TPC-1 cells were exposed to 200 μM palmitic acid (PA; Sigma-Aldrich) for 24 h after hypoxia.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">| Cell transfection</head><p>The specific shRNA targeting CPT1A (shRNA-CPT1A-1: CAGTGG-TATTTGAAGTTAA; shRNA-CPT1A-2: CCATGAAGCTCTTAGACAA), CPT1A-specific pcDNA overexpression vector (OV-CPT1A), and corresponding control (NC: CCGGCAACAAGATGAAGAGCACCAAC TC) were synthesized by GenePharma (Shanghai, China). These recombinants were transfected into TPC-1 cells using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. After 48 h transfection, cells were harvested for subsequent experiments.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">| Cell counting kit-8 (CCK-8) assay</head><p>After transfection and treated with or without hypoxia and PA, cells were seeded into a 96-well plate and cultured at 37°C. After 12, 24, and 48 h, 10 µL CCK-8 solution was added to each well. Plates were incubated for 2 h, and the absorbance was measured with a microplate reader (Thermo Fisher Scientific) at 450 nm.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">| Evaluation of mitochondrial membrane motential (MMP)</head><p>Cationic dye 5, 5′, 6, 6′-tetrachloro-1, 1′, 3, 3-tetraethylbenzimidazolylcarbocyanine iodide (JC-1, Sigma-Aldrich, MO, USA) staining was conducted to assess mitochondrial membrane motential (MMP). Briefly, after transfected with sh-CPT1A or OV-CPT1A in the presence or absence of hypoxia and PA, TPC-1 cells were collected and incubated with JC-1 for 20 min at 37°C, and were then detected with fluorescence microscope. Red fluorescence represented a potential-dependent aggregation in the mitochondria, reflecting ΔΨm. Green emission of the dye represented the monomeric form of JC-1, appearing in the cytosol after mitochondrial membrane depolarization. The wavelengths of excitation and emission were 514 nm and 529 nm for detection of monomeric form of JC-1, while 585 nm and 590 nm were used to detect aggregation of JC-1.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5">| Detection of free fatty acids</head><p>TPC-1 cells were transfected with sh-CPT1A or OV-CPT1A, followed by treatment of hypoxia with or without PA. Firstly, treated cells were lysed with RIPA buffer for 45 min. Then cell homogenates were obtained by chlo-roform and methanol solution (chloroform: metha-nol=2:1, followed by lipid extraction. The level of free fatty acids was detected by using corresponding commercial kits (Bioassay Systems).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6">| Flow cytometric analysis</head><p>Cell apoptosis was analyzed by flow cytometry using annexin V-PI assay kit. Cells were treated with hypoxia with or without PA for 24 h after transfection. The treated cells were collected for annexin V-PI staining according to the manufacturer's instructions (BD Biosciences PharMingen). Flowjo software (Tree Star) was applied for apoptosis analysis. were grown, and 5 × 10 7 /mL cell suspensions were prepared in 100 μL PBS and subcutaneously injected into the back of each mouse on the right side. Mouse weight and tumor size were monitored daily and recorded, and the tumor volumes were calculated every 3 days using the formula: volume = (length × width 2 )/2. Thirty days later, the mice were killed and the tumor was immediately harvested, weighed and collected for following assays.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7">| Xenograft experiments</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8">| Oil red O staining</head><p>Oil Red O staining was carried out to detect the Lipid deposition in tumor tissues of mice from different groups. 0.5 g Oil Red O powder (Sigma Chemical Co.) was evenly dissolved in 100 mL of isopropanol to prepare stock solution, which was then diluted with distilled water at the ratio of 3:2 and filtrated to make working solution. The sections of tumor tissues were fixed and prewetted with 60% isopropanol, and then stained with Oil Red O working solution for 15 min. The positive area was measured with the ImageJ 1.47 software.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.9">| Detection of oxidative stress</head><p>TPC-1 cells were seeded in 96-well plates at a density of 1 × 10 4 cells/well, while the mice tissues were homogenized. Following treatment, the activity of SOD in media was analyzed using a SOD kit from Nanjing Jiancheng Bioengineering Institute. The MDA level was measured with an MDA kit (Beyotime Institute of Biotechnology, Jiangsu, China). For colorimetric analysis, the absorbance at 532 nm was recorded using a microplate reader (Spectra Max 190; Molecular Devices, LLC).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.10">| Measurement of inflammatory factors</head><p>The contents of IL-1β, IL-6 and TNF-α in TPC-1 cells and mice tissues were determined with ELISA kits according to the relevant kits. The optical density of each well was assayed at 450 nm with a microplate spectrophotometer. Finally, the contents were calculated according to the standard curves.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.11">| Quantitative real-time polymerase chain reaction (qRT-PCR)</head><p>Total RNA was extracted from cells using the TRIzol kit (Invitrogen) according to the manufacturer's instructions. A NanoDrop 3000 spectrophotometer (ThermoScientific, Waltham, MA) was used to confirm the sufficient quality of total RNA according to the manufacturer's protocol. Then, the RNA was converted to cDNA by PrimeScript RT Master Mix (Takara, Japan). The primer sequences for PCR are presented as below: CPT1A: 5′-TGGGATCGATCGTCACCTCT-3′ (forward) and 5′-TTTCCAGCCCAGCACATGAA-3′ (reverse); HIF-1α: 5′-AG AGGTTGAGGGACGGAGAT-3′ (forward) and 5′-CTCCGACATTGGG AGCTCAT-3′ (reverse); GAPDH: 5′-GGGAAACTGTGGCGTGAT-3′ (forward) and 5′-GAGTGGGTGTCGCTGTTGA-3′ (reverse). The real-time quantitative PCR used ChamQTM SYBR ® qPCR Master Mix (Vazyme, Nanjing, China). The relative mRNA level was normalized with GAPDH by 2 -ΔΔCt method.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.12">| Western blot analysis assay</head><p>The total proteins were extracted from cells and tissues using RIPA buffer (Auragene) and quantified using BCA Protein Assay Kit (Dingguo). An equal amount of protein was loaded on 10% SDS-polyacrylamide gels and then transferred to a Pure Nitrocellulose Blotting membrane (Pall Life Science). After being blocked with 5% nonfat milk, primary antibodies targeting CPT1A (1:1000, ab220789; Abcam), HIF-1α (1:1000, ab1; Abcam), VEGF (1:1000, ab32152; Abcam), Bax (1:1000, ab32503; Abcam), Casp3 (1:1000, ab32351; Abcam), GLUT1 (1:1000, ab150299; Abcam) and GAPDH (1:1000, ab8245; Abcam) were added and incubated overnight at 4°C. The blots were incubated with horseradish peroxidaseconjugated secondary antibody at room temperature for 1 h. The protein bands were detected by an ECL detection system and analyzed by ImageJ software.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.13">| Statistical analysis</head><p>Statistical analysis was performed using SPSS 23.0 statistical software (SPSS) and GraphPad Prism 5.0 (GraphPad SoftwareA). All data were reported as mean ± standard deviation (SD). The data were in accordance with the normal distribution by Shapiro-Wilk test.</p><p>Significant differences between groups were analyzed by one-way ANOVA followed by Bonferroni post hoc comparisons tests as both normality tests and equality tests passed (SigmaPlot 14.0; Systat Software). Values of p &lt; .05 were considered to be statistically significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">| RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">| Hypoxia promotes the expressions of CPT1A and HIF-1α in PTC cells</head><p>Firstly, we detected the mRNA and protein expressions of CPT1A and HIF-1α in PTC cells. The data showed that the expressions of both CPT1A and HIF-1α were significantly increased in PTC cells compared with the control cells Nthy-ori 3-1 (Figure <ref type="figure">1a-d</ref>). Combined with the above results, we chose the cell line TPC-1 for the following assays. Then, TPC-1 cells were placed in hypoxic environment (1% O 2 and 5% CO 2 ) for 12, 24, 48 and 72 h. We found that the cell viability of TPC-1 cells were reduced by hypoxia in a timedependent manner (Figure <ref type="figure">1e</ref>). And, mRNA and protein levels of CPT1A and HIF-1α were remarkably elevated after hypoxia treatment in this PTC cell line (Figure <ref type="figure">1f-i</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">| The effects of CPT1A expression on PTC cells under hypoxia condition</head><p>To investigate the role of CPT1A in PTC progression, we transfected sh-CPT1A-1/2 and OV-CPT1A into TPC-1 cells to knockdown and overexpress CPT1A, respectively. The results from qRT-PCR and western blot assay showed that sh-CPT1A-1 led to lower expression of CPT1A in TPC-1 cells (Figure <ref type="figure">2a,</ref><ref type="figure">b</ref>). Therefore, sh-CPT1A-1 was chosen for the subsequent study (named as sh-CPT1A). CCK-8 assay indicated that cell proliferation was notably increased after transfection with OV-CPT1A but inhibited in TPC-1 transfected with sh-CPT1A compared with the negative control (Figure <ref type="figure">2c</ref>). Then we detected the effects of CPT1A under hypoxia condition on cell proliferation. The data showed that after treatment of hypoxia for 24 h, the cell proliferation declined in each groups. The OV-CPT1A group had the higher cell proliferation capacity compared with the negative control while sh-CPT1A group was lower (Figure <ref type="figure">2d</ref>). In addition, hypoxia enhanced the levels of ROS and MDA and reduced the activity of SOD. PA treatment further added the ROS and MDA level and decreased SOD activity. However, CPT1A overexpression reversed the effects of hypoxia and PA while CPT1A silencing showed the opposite effects (Figure <ref type="figure">2e</ref>). The experiments for the detection of inflammation factors showed a similar trend to that of oxidative stress (Figure <ref type="figure">2f</ref>). Moreover, aggregated JC-1 in mitochondria of control cells exhibited red fluorescence, and exposure to hypoxia and PA increased dissipation of ΔΨm, with increased green fluorescence (monomeric JC-1) in mitochondria. CPT1A overexpression or silencing increased or reduced the decreased red fluorescence by hypoxia and PA and reduced or increased green fluorescence (Figure <ref type="figure">2g</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">| CPT1A ameliorates PA-induced abnormal lipid metabolism in TPC-1 cells treated with hypoxia</head><p>As shown in Figure <ref type="figure">3a</ref>, PA treatment significantly reduced cell viability of TPC-1 cells after hypoxia. Upregulation of CPT1A rehabilitated the viability after treatment of both hypoxia and PA, and CPT1A silencing further repressed cell viability. In addition, the addition of PA resulted in increased level of free fatty acids in hypoxia-induced TPC-1 cells. CPT1A overexpression reduced the contents of free fatty acids but CPT1A knockdown increased the level of free fatty acids compared with the hypoxia+PA group (Figure <ref type="figure">3b</ref>). Furthermore, PA evidently elevated the rate of cell apoptosis of hypoxia-induced cells. However, the cell apoptosis was inhibited by transfection with OV-CPT1A and aggravated by transfection with sh-CPT1A (Figure <ref type="figure">3c</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">| CPT1A has an effect on tumor growth and lipid deposition in vivo</head><p>To verify the results obtained from cell experiments above, a xenograft PTC mouse model was established by injecting with TPC-1 cells transfected with OV-CPT1A or sh-CPT1A (Figure <ref type="figure">4a</ref>).</p><p>The body weight, tumor volume and tumor weight in OV-CPT1A group were greatly higher compared with the negative control, but CPT1A silencing decreased those in mice (Figure <ref type="figure">4b-d</ref>). Additionally, Oil Red O staining revealed that lipid deposition was significantly decreased after CPT1A overexpression while downregulation of CPT1A obviously increased the level lipid deposition (Figure <ref type="figure">4e</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5">| The changes of CPT1A expression influences multiple indicator in mice tumor tissues</head><p>As shown in Figure <ref type="figure">5a</ref>, the levels of ROS and MDA in tumor tissues were found to be abrogated and SOD activity was increased after transfection with OV-CPT1A whereas the tendency was reversed by sh-CPT1A. The production of IL1β, IL6 and TNF in tumor tissues were inhibited by CPT1A overexpression but promoted by CPT1A silencing (Figure <ref type="figure">5b</ref>). Moreover, upregulation of CPT1A enhanced the protein levels of HIF-1α, CPT1A, VEGF and GLUT1 and reduced the generations of Bax and Casp3, whereas CPT1A silencing had the opposite effects on these protein levels in tumor tissues (Figure <ref type="figure">5c</ref>). Thyroid cancer is one of the most common endocrine tumors, ranking 9th among the most common malignant tumors worldwide, with a global incidence increasing at an annual rate of 20% <ref type="bibr" target="#b14">(Laha et al., 2020)</ref>.</p><p>PTC is the most frequent pathologic type, accounting for more than 85% of thyroid cancers <ref type="bibr" target="#b11">(Ijaz &amp; Yin, 2023)</ref>. PTC usually has a favorable prognosis, with a 5-year postoperative survival rate of more than 90%, and some are even considered not to require immediate surgery <ref type="bibr" target="#b15">(Lam, 2022)</ref>. However, due to the multifocal nature of PTC and early  lymph node metastasis, the recurrence rate is as high as 35%, and the 10-year disease-specific survival rate for progressive PTC is less than 50% <ref type="bibr" target="#b24">(Maciel et al., 2022)</ref>. In this study, we found that Hypoxia affected PTC cell viability, oxidative stress, inflammation, lipid metabolism and even apoptosis. Overexpression of CPT1A reversed the bad effects of hypoxia on PTC cells and promoted lipid metabolism reprogramming to help cells adapt to low oxygen environment and restrain mechanism of cell death.</p><formula xml:id="formula_0">F I G U R E 2</formula><p>Hypoxia is an important factor in promoting thyroid cancer progression and metastasis <ref type="bibr" target="#b2">(Bao &amp; Wong, 2021)</ref>. Indeed, solid tumors often grow in a hypoxic environment and thus their biological properties are already altered <ref type="bibr" target="#b4">(Chen &amp; Lou, 2017;</ref><ref type="bibr" target="#b6">Chiu et al., 2017;</ref><ref type="bibr" target="#b28">Park et al., 2023)</ref>. In this state, hypoxia-inducible factors play important roles, and the upregulation of HIF-1α leads to a series of changes, including the promotion of erythropoiesis, the increase of oxygen supply to tumor tissues, the promotion of intra-tumor angiogenesis, the mediation of glycolytic function in the state of ischemia and hypoxia, and the inhibition of apoptosis <ref type="bibr" target="#b32">(Schödel et al., 2016)</ref>. In this study, we found that hypoxia brought about lower cell viability, higher expressions of CPT1A and HIF-1α, higher levels of oxidative stress and inflammatory response.</p><p>Metabolic reprogramming helps tumor cells alter their metabolic capacity to support increased energy demands due to their rapid growth and proliferation <ref type="bibr" target="#b7">(Hanahan &amp; Weinberg, 2011)</ref>. Rapidly proliferating cells such as cancer cells show the alteration of lipid metabolism <ref type="bibr" target="#b23">(Luo et al., 2017)</ref>. Numerous evidence show that reprogramming of fatty acids metabolism happens in lung, prostate, gastric, ovarian and breast cancer cells, with the characteristics of active fatty acids synthesis and/or β-oxidation <ref type="bibr" target="#b25">(Mashima et al., 2009;</ref><ref type="bibr" target="#b27">Orita et al., 2008)</ref>. Some studies have reported the changes of fatty  <ref type="bibr">et al., 2018;</ref><ref type="bibr" target="#b21">Lu et al., 2016)</ref>. Lu et al. performed a Multi-Omics analysis of fatty acid metabolism in thyroid carcinoma and fount that CPT1A expression level was significantly elevated in PTC, and it is possible that high level of CPT1A was associated with poor prognosis in PTC <ref type="bibr" target="#b22">(Lu et al., 2021)</ref>. Our results also showed that the levels of CPT1A and HIF-1αwere upregulated in several PTC cell lines compared with the Nthy-ori 3-1 control cells.</p><p>CPT1 family is the first rate-limiting enzyme in fatty acid oxidation (FAO), playing a significant role in metabolic adaptation in cancer pathogenesis <ref type="bibr" target="#b3">(Casals et al., 2016)</ref>. CPT1A is one member of CPT1 family and controls the entry of fatty acids into the mitochondria for oxidation <ref type="bibr" target="#b34">(Tan et al., 2018)</ref>. HIF-1α also has an effect on cellular lipid metabolism <ref type="bibr" target="#b33">(Seo et al., 2020)</ref>. In addition, upregulated HIF-1α can promote fatty acid metabolism, maintain cellular energy demand, and reduce intracellular lipid accumulation by activating pathway pathways such PPARs in a hypoxic environment <ref type="bibr" target="#b16">(Lee et al., 2021)</ref>. At the same time, HIF-1α enhances the expression activity of fatty acid metabolizing enzymes and antioxidative stress enzymes, so that reactive oxygen species or peroxides generated during mitochondrial metabolism can be reduced and degraded, thus reducing cellular oxidative stress injury <ref type="bibr" target="#b12">(Jassim et al., 2021;</ref><ref type="bibr" target="#b17">Li et al., 2019)</ref>. In the current study, we overexpressed and silenced CPT1A to explore the effects of CPT1A expression on cell injury and fatty acid metabolism in PTC cells. The data revealed that CPT1A overexpression reduced the cell injury induced by hypoxia by inhibiting oxidative stress and inflammatory response, as well as maintaining MMP. Moreover, the treatment of PA further exacerbated hypoxia-induced cell damage, and CPT1A overexpression reversed the effects of PA by reducing free fatty acid and inhibiting cell apoptosis. Animal experiments also proved the results from our cell assays. CPT1A overexpression aggravated PTC tumor growth and reduced lipid deposition in tissues. However, CPT1A silencing revealed opposite effects to CPT1A overexpression in each experiments. It's worth noting that HIF-1 has been proved to alter lipid accumulation, beta-oxidation and lipolysis in cancer, but we did not deeply observe the relationship between CPT1A and HIF-1α in PTC, which need to be explored in further study.</p><p>In summary, we demonstrated that hypoxia reprogrammed the lipid metabolism of PTC cells to adapt to the hypoxic environment by inducing high expression of CPT1A, which resulted in supplying tumor cells with energy while inhibiting oxidative stress-induced cellular damage (especially mitochondria) and apoptosis. CPT1A dysregulation has an important role in hypoxia-induced pathological processes in PTC development, which not only enhance our understanding of the pathogenesis of hypoxia-regulated cancer but also lead to the development of novel therapeutic targets for PTC treatment.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>All experiments were conducted according to the guidelines established by the Animal Care and Use Committee of Zhao Feng Hua Biotechnology (Nanjing) Co., Ltd. (No. IACUC-20230401-1) and strictly followed the Guidelines for the Care and Use of Laboratory Animals by National Institute of Health. Female Balb/c nude mice (4 weeks of age) were purchased from the Shanghai Sipple-Bikai Laboratory Animal Co., Ltd. and were housed under controlled conditions including a room temperature of 22 ± 1°C with 12:12-h light-dark cycle. The animals were fed with standard food pellets and water ad libitum. Twenty mice were randomly divided into 4 groups (n = 5). TPC-1 cells transfected with NC, OV-CPT1A and sh-CPT1A</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>F</head><label></label><figDesc>I G U R E 1 Hypoxia promotes the expressions of CPT1A and HIF-1α in PTC cells. mRNA expression (a) and protein level (b) of CPT1A in PTC cells were detected by qRT-PCR and western blot assay, respectively. mRNA expression (c) and protein level (d) of HIF-1α in PTC cells were detected by qRT-PCR and western blot assay, respectively. (e) CCK-8 assay was measured to assess cell viability under hypoxia. mRNA expression (f) and protein level (g) of CPT1A in PTC cells after treatment of hypoxia were detected by qRT-PCR and western blot assay, respectively. mRNA expression (h) and protein level (i) of HIF-1α in PTC cells after treatment of hypoxia were detected by qRT-PCR and western blot assay, respectively. Results are the mean ± SD. **p &lt; .01, ***p &lt; .001. F I G U R E 2 (See caption on next page).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc>The effects of CPT1A expression on PTC cells under hypoxia condition. mRNA expression (a) and protein level (b) of CPT1A in TPC-1 cells were detected by qRT-PCR and western blot assay, respectively. (c) CCK-8 assay was measured to assess cell proliferation after CPT1A overexpression or silencing. (d) The ratio of cell proliferation under hypoxia/normal oxygen. (e) Levels of ROS, SOD and MDA were detected by corresponding kits. (f) The levels of IL-1β, IL-6 and TNF-α were measured by ELISA. (g) The level of mitochondrial membrane potential was detected by JC-1. Results are the mean ± SD. *p &lt; .05, **p &lt; .01, ***p &lt; .001.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>F</head><label></label><figDesc>I G U R E 3 CPT1A ameliorates PA-induced abnormal lipid metabolism in hypoxia-induced TPC-1 cells. (a) CCK-8 assay was measured to assess cell viability in TPC-1 cells treated with hypoxia and PA after CPT1A overexpression or silencing. (b) The level of free fatty acids was evaluated by fatty acid kit. (c) Flow cytometry was conducted to detect cell apoptosis rate in TPC-1 cells. Results are the mean ± SD. *p &lt; .05, **p &lt; .01, ***p &lt; .001.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc>acids level in PTC tissues, which indicate fatty acids metabolism may be involved in PTC development (Abooshahab et al., 2020; Li F I G U R E 4 Effects of CPT1A on tumor growth and lipid deposition in vivo. (a) The xenograft mouse model was established by injecting with TPC-1 cells transfected with sh-CPT1A or OV-CPT1A. The body weight (b), tumor volume (c) and tumor weight (d) of mice transfected with sh-CPT1A or OV-CPT1A were observed. (e) Oil Red O staining was used to assess the level lipid deposition. Results are the mean ± SD. *p &lt; .05, **p &lt; .01, ***p &lt; .001.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>F</head><label></label><figDesc>I G U R E 5 The changes of CPT1A expression influences multiple indicators in mice tumor tissues. (a) Levels of ROS, SOD and MDA were detected by corresponding kits. (b) The levels of IL-1β, IL-6 and TNF-α were measured by ELISA. (c) Levels of HIF-1α, CPT1A, VEGF, Bax, Casp3 and GLUT1 were measured by western blot assay. Results are the mean ± SD. *p &lt; .05, **p &lt; .01, ***p &lt; .001.</figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="8" xml:id="foot_0"><p>of 11 | LIANG ET AL. 10982299, 2024, 2, Downloaded from https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/ddr.22168 by Zhongshan University, Wiley Online Library on [08/06/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p>10982299, 2024, 2, Downloaded from https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/ddr.22168 by Zhongshan University, Wiley Online Library on [08/06/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</p></note>
		</body>
		<back>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DATA AVAILABILITY STATEMENT</head><p>Data are contained within the article.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ORCID</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Liang Zong</head><p>http://orcid.org/0009-0008-9534-0214</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST STATEMENT</head><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Plasma metabolic profiling of human thyroid nodules by gas chromatography-mass spectrometry (GC-MS)-based untargeted metabolomics</title>
		<author>
			<persName><forename type="first">R</forename><surname>Abooshahab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hooshmand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Razavi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gholami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sanoie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hedayati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Cell and Developmental Biology</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">385</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Suppression of B-Raf(V600E) cancers by MAPK hyper-activation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Atiq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eldad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Smeir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bar-Tana</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="18694" to="18704" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Wong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Hypoxia, metabolic reprogramming, and drug resistance in liver</title>
		<imprint>
			<date type="published" when="2021">2021</date>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">1715</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Carnitine palmitoyltransferase 1C: From cognition to cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Casals</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Zammit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Herrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fadó</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rodríguez-Rodríguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Serra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Progress in Lipid Research</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="134" to="148" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Hypoxia inducible factors in hepatocellular carcinoma</title>
		<imprint>
			<date type="published" when="2017">2017</date>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="46691" to="46703" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H H</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S A</forename><surname>Mcleod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Newbold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Haymart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thyroid cancer. The Lancet</title>
		<imprint>
			<biblScope unit="volume">401</biblScope>
			<biblScope unit="page" from="1531" to="1544" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/ CD39L1 in hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K C</forename><surname>Chiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P W</forename><surname>Tse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M J</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Di Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K H</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Koh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H C</forename><surname>Tsang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">O L</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C L</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>An</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Communications</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">111268</biblScope>
			<date type="published" when="2017">2017. 2023</date>
		</imprint>
	</monogr>
	<note>The EMBO Journal</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Hallmarks of cancer: The next generation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hanahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Weinberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="646" to="674" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Butyrate enhances CPT1A activity to promote fatty acid oxidation and iTreg differentiation</title>
		<author>
			<persName><forename type="first">F</forename><surname>Hao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<date type="published" when="2021">2021. 2014681118</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Tumor hypoxia as a barrier in cancer therapy: Why levels matter</title>
		<author>
			<persName><forename type="first">T</forename><surname>Hompland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Fjeldbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lyng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">499</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Savage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Ivey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Kennedy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Whiteaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Eskandari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Delisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gentile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Huntoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">J</forename><surname>Voytovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">J</forename><surname>Shire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Gygi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Paulovich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Reports Medicine</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">100471</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Papillary thyroid carcinoma with squamous dedifferentiation: A potential diagnostic pitfall</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ijaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Yin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Research</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="255" to="258" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Oxidative stress and hypoxia modify mitochondrial homeostasis during glaucoma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Jassim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pappenhagen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Nsiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Inman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antioxidants &amp; Redox Signaling</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1341" to="1357" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Adrenomedullin2 stimulates progression of thyroid cancer in mice and humans under nutrient excess conditions</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Koh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Jun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Koo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">E</forename><surname>Kang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of Pathology</title>
		<imprint>
			<biblScope unit="volume">258</biblScope>
			<biblScope unit="page" from="264" to="277" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">New therapies for advanced thyroid cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Laha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nilubol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boufraqech</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Endocrinology</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">82</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Histopathological assessment for papillary thyroid carcinoma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Lam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Methods in Molecular Biology</title>
		<imprint>
			<biblScope unit="volume">2534</biblScope>
			<biblScope unit="page" from="93" to="108" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">HIF-1-independent mechanisms regulating metabolic adaptation in hypoxic cancer cells</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Golinska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Griffiths</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cells</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">2371</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">HIF-1α protects against oxidative stress by directly targeting mitochondria</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">N</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Redox Biology</title>
		<imprint>
			<biblScope unit="page">101109</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">exacerbates LPSinduced sepsis by driving CPT1a-mediated fatty acid oxidation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>You</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ikezoe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mitochondrial STAT</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="976" to="998" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>Theranostics</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Tang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Molecular Medicine</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="3006" to="3014" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">regulation of papillary thyroid carcinoma by long noncoding RNAs</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">X</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Seminars in Cancer Biology</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="253" to="260" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Noninvasive diagnosis of papillary thyroid microcarcinoma: a NMRbased metabolomics approach</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Miccoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="81768" to="81777" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Multi-omics analysis of fatty acid metabolism in thyroid carcinoma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Miccoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Oncology</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">737127</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Emerging roles of lipid metabolism in cancer metastasis</title>
		<author>
			<persName><forename type="first">X</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecular Cancer</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">76</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Isolated adrenal metastases of papillary thyroid carcinoma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Maciel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vilar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Leite</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endokrynologia Polska</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="167" to="168" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Risk factors for lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Okabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Miyata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Matsuura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sugimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tsuruo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Seimiya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in Endocrinology</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1556" to="1562" />
			<date type="published" when="2009">2020. 2009</date>
		</imprint>
	</monogr>
	<note>Cancer Science</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Micro-RNAs signatures in papillary thyroid carcinoma</title>
		<author>
			<persName><forename type="first">N</forename><surname>Mastronikolis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tsiambas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Roukas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fotiades</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chrysovergis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Papanikolaou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kyrodimos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mastronikoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Niotis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ragos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="2144" to="2146" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors</title>
		<author>
			<persName><forename type="first">H</forename><surname>Orita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Coulter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tully</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Kuhajda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gabrielson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical Cancer Research</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="2458" to="2464" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Enhanced glutaminolysis drives hypoxia-induced chemoresistance in pancreatic cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Min</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Han</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="735" to="752" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Carnitine palmitoyltransferase 1 regulates prostate cancer growth under hypoxia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Rios-Colon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Stocks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">R</forename><surname>Schlaepfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Deep</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">6302</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Poloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Mcnulty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Elson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gassmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Arbeit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Johnson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="4010" to="4015" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">R</forename><surname>Schlaepfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Joshi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="page">46</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<author>
			<persName><forename type="first">J</forename><surname>Schödel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Grampp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Maher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Moch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Ratcliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Russo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Mole</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Hypoxia, hypoxia-inducible transcription factors, and renal cancer</title>
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="646" to="657" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Seo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fukuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Chun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Communications Biology</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">638</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Targeting CPT1Amediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Onuchic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Bode</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Theranostics</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="2329" to="2347" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Pu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="6025" to="6040" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The cancer metabolic reprogramming and immune response</title>
		<author>
			<persName><forename type="first">L</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Oyang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Liao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecular Cancer</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">28</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">ARHGAP36 regulates proliferation and migration in papillary thyroid carcinoma cells</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Molecular Endocrinology</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
